When less is more: The association between the expression of polymorphic CYPs and AFB1‐induced HCC

Asmaa Ashraf Mohamed; Monica Armanious; Rana W. Bedair; Nada Sherif Amin; Hend M. El Tayebi

doi:10.1111/eci.14297

journal article Aug 05, 2024

When less is more: The association between the expression of polymorphic CYPs and AFB1‐induced HCC

Asmaa Ashraf Mohamed Monica Armanious Rana W. Bedair Nada Sherif Amin Hend M. El Tayebi

European Journal of Clinical Investigation Vol. 54 No. 12 · Wiley

View at Publisher Save 10.1111/eci.14297

Abstract

AbstractBackgroundAn individual’s genetic fingerprint is emerging as a pivotal predictor of numerous disease‐ and treatment‐related factors. Single nucleotide polymorphisms (SNPs) in drug‐metabolizing enzymes play key roles in an individual’s exposure to a malignancy‐associated risk, such as Aflatoxin B1 (AFB1)‐induced hepatocellular carcinoma (HCC).AimThis study aimed at reviewing literature on the polymorphisms that exist in CYP enzymes and their possible link with susceptibility to AFB1‐induced HCC.Materials & MethodsA set of keywords associated with the study subject of interest was used to search the Google Scholar and the PubMed database. The last ten years’ worth of research projects were included in the results filter. The research involved HCC patients and any connection between polymorphic forms of CYP enzymes and their susceptibility to AFB1‐induced HCC, including older but significant data.ResultsVariations in CYP1A2 and CYP3A4 were reported to impact the rate and magnitude of AFB1 bio‐activation, thus influencing an individual’s vulnerability to develop HCC. In HCC patients, the activity of CYP isoforms varies, where increased activity has been reported with CYP2C9, CYP2D6, and CYP2E1, while CYP1A2, CYP2C8, and CYP2C19 exhibit decreased activity. CYP2D6*10 frequency has been discovered to differ considerably in HCC patients. Rs2740574 (an upstream polymorphism in CYP3A4 as detected in CYP3A4*1B) and rs776746 (which affects CYP3A5 RNA splicing), both of which influence CYP3A expression, thus impacting the variability of AFB1‐epoxide adducts in HCC patients.DiscussionCYP1A2 is the primary enzyme accountable for the formation of harmful AFBO globally. CYP3A4, CYP3A5, CYP3A7, CYP2B7, and CYP3A3 are also implicated in the bio‐activation of AFB1 to mutagenic metabolites. It is thought that CYP3A4 is the protein that interacts with AFB1 metabolism the most.ConclusionPolymorphic variants of CYP enzymes have a functional impact on the susceptibility to AFB1‐induced HCC. Outlining such variation and their implications may provide deeper insights into approaching HCC in a more personalized manner for guiding future risk‐assessment, diagnosis, and treatment.

Topics

No keywords indexed for this article. Browse by subject →

References

61

[1]

10.3748/wjg.14.4300

[2]

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al.

CA: A Cancer Journal for Clinicians 10.3322/caac.21492

[3]

10.12688/f1000research.7340.1

[4]

10.1016/j.fct.2018.11.047

[5]

10.3390/nu14081652

[6]

10.1016/j.ejca.2018.02.010

[7]

10.1038/s41392-021-00713-1

[8]

10.1016/0006-2952(75)90460-8

[9]

10.1016/j.trsl.2018.09.001

[10]

10.3920/wmj2020.2621

[11]

Auchus RJ (2015)

[12]

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

J. Andrew Williams, Ruth Hyland, Barry C. Jones et al.

Drug Metabolism and Disposition 10.1124/dmd.104.000794

[13]

10.1038/nrd1851

[14]

10.3390/toxins13060384

[15]

10.3390/foods13010163

[16]

10.3390/biology12020205

[17]

10.1093/carcin/bgu003

[18]

10.1073/pnas.1700759114

[19]

10.1016/j.dnarep.2023.103544

[20]

10.1016/j.dnarep.2019.03.004

[21]

Yao J‐G "Interaction of DNA repair gene polymorphisms and aflatoxin B1 in the risk of hepatocellular carcinoma" Int J Clin Exp Pathol (2014)

[22]

10.1179/2049396714y.0000000069

[23]

10.1016/j.tiv.2009.12.022

[24]

10.3390/ijms16046945

[25]

10.2527/2002.8051250x

[26]

10.5681/apb.2013.076

[27]

10.1016/j.tiv.2012.03.003

[28]

10.1158/1078-0432.ccr-11-3225

[29]

10.4161/jkst.20045

[30]

Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures

Richard E. Randall, Stephen Goodbourn

Journal of General Virology 10.1099/vir.0.83391-0

[31]

10.1146/annurev.biochem.67.1.227

[32]

10.1186/s13027-017-0127-8

[33]

10.1186/s40360-023-00683-w

[34]

10.1158/1940-6207.capr-13-0430

[35]

10.1155/2016/1972793

[36]

10.1073/pnas.2007412117

[37]

10.1016/j.toxrep.2019.05.008

[38]

10.1016/j.bcp.2020.113912

[39]

10.1158/1535-7163.mct-15-0274

[40]

10.2174/1389200219666180529113818

[41]

10.3390/ijms222312808

[42]

10.1016/b978-0-12-386454-3.00299-2

[43]

10.1021/tx500444e

[44]

10.1371/journal.pone.0082562

[45]

10.18632/oncotarget.9437

[46]

10.1186/s12967-021-03038-3

[47]

10.2174/1389200223666220328143828

[48]

10.18632/oncotarget.14165

[49]

10.3389/fmicb.2022.988083

[50]

10.22034/apjcp.2018.19.8.2057

Showing 50 of 61 references

Metrics

11

Citations

61

References

Details

Published: Aug 05, 2024
Vol/Issue: 54(12)
License: View

Authors

A

Asmaa Ashraf Mohamed